TCRX Insider Trading

Insider Ownership Percentage: 2.76%
Insider Buying (Last 12 Months): $86,659.98
Insider Selling (Last 12 Months): $951,885.08

TScan Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at TScan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500k$0$500kTotal Insider BuyingTotal Insider Selling

TScan Therapeutics Share Price & Price History

Current Price: $1.38
Price Change: Price Increase of +0.03 (2.22%)
As of 03/31/2025 05:00 PM ET

This chart shows the closing price history over time for TCRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.35Closing price on 03/30/25:

SEC Filings (Institutional Ownership Changes) for TScan Therapeutics (NASDAQ:TCRX)

82.83% of TScan Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TCRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.08Mbought$1.63MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
TScan Therapeutics logo
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More on TScan Therapeutics

Today's Range

Now: $1.38
Low: $1.28
High: $1.45

50 Day Range

MA: $2.04
Low: $1.35
High: $2.58

52 Week Range

Now: $1.38
Low: $1.28
High: $9.69

Volume

862,980 shs

Average Volume

334,676 shs

Market Capitalization

$78.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Who are the company insiders with the largest holdings of TScan Therapeutics?

TScan Therapeutics' top insider shareholders include:
  1. Lynx1 Capital Management Lp (Major Shareholder)
  2. Timothy J Barberich (Director)
  3. Barbara Klencke (Director)
  4. Zoran Zdraveski (Insider)
Learn More about top insider investors at TScan Therapeutics.

Who are the major institutional investors of TScan Therapeutics?

TScan Therapeutics' top institutional investors include:
  1. Lynx1 Capital Management LP — 10.04%
  2. Adage Capital Partners GP L.L.C. — 6.56%
  3. Geode Capital Management LLC — 1.80%
  4. abrdn plc — 1.66%
  5. Dimensional Fund Advisors LP — 0.52%
  6. Tocqueville Asset Management L.P. — 0.49%
Learn More about top institutional investors of TScan Therapeutics stock.

Which major investors are selling TScan Therapeutics stock?

In the previous quarter, TCRX stock was sold by these institutional investors:
  1. Adage Capital Partners GP L.L.C.
  2. Marshall Wace LLP
  3. Jacobs Levy Equity Management Inc.
  4. Renaissance Technologies LLC
  5. Geode Capital Management LLC

Which major investors are buying TScan Therapeutics stock?

In the last quarter, TCRX stock was acquired by institutional investors including:
  1. abrdn plc
  2. Dimensional Fund Advisors LP
  3. Lynx1 Capital Management LP
  4. Tang Capital Management LLC
  5. Dauntless Investment Group LLC
  6. Bridgeway Capital Management LLC
  7. BNP Paribas Financial Markets
  8. Tocqueville Asset Management L.P.
Within the previous year, these company insiders have bought TScan Therapeutics stock:
  1. Lynx1 Capital Management Lp (Major Shareholder)
  2. Timothy J Barberich (Director)
  3. Barbara Klencke (Director)
Learn More investors buying TScan Therapeutics stock.